{"id":"NCT00516074","sponsor":"AstraZeneca","briefTitle":"A Study to Assess the Effect of Exenatide Treatment on Mean 24-Hour Heart Rate in Patients With Type 2 Diabetes","officialTitle":"A Study to Assess the Effect of Exenatide Treatment on Mean 24-Hour Heart Rate in Patients With Type 2 Diabetes","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-09","primaryCompletion":"2008-04","completion":"2008-04","firstPosted":"2007-08-14","resultsPosted":"2009-06-12","lastUpdate":"2015-04-07"},"enrollment":54,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"exenatide","otherNames":["Byetta","AC2993","LY2148568"]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"Exenatide Arm","type":"EXPERIMENTAL"},{"label":"Placebo Arm","type":"PLACEBO_COMPARATOR"}],"summary":"This study will explore the effect of exenatide (given twice a day) versus placebo (given twice a day) treatment on change in mean 24-hour heart rate over a 12 week period of drug exposure in patients with type 2 diabetes.","primaryOutcome":{"measure":"Change in Mean 24-hour Heart Rate From Baseline to Endpoint","timeFrame":"12 weeks","effectByArm":[{"arm":"Exenatide BID","deltaMin":74.83,"sd":2.04},{"arm":"Placebo","deltaMin":74.47,"sd":2.08}],"pValues":[{"comp":"OG000 vs OG001","p":"0.1585"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":8},"locations":{"siteCount":6,"countries":["Canada","Netherlands"]},"refs":{"pmids":["20109208"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1},"commonTop":["Nausea","Influenza","Headache","Hyperglycemia","Vomiting"]}}